Programmed death‐ligand 1 testing of lung cancer cytology specimens obtained with bronchoscopy

Stoy, Sean; Rosen, Lauren; Mueller, Jeffrey; Murgu, Septimiu

doi:10.1002/cncy.21941

Cited by 65 publications

(69 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The recently completed second phase of Blueprint compared five PD-L1 detection assays including the new assay for avelumab (Dako 73-10), which was found to stain a slightly higher percentage of tumor cells than other assays [21]. Phase II demonstrated the utility of training platforms for standardizing scoring among pathologists and showed that there was a good correlation of PD-L1 expression between tumor and cytology specimens [19,21], a finding supported by other recent studies [22,23].…”

mentioning

confidence: 76%

Patient Selection for Anti-PD-1/PD-L1 Therapy in Advanced Non-Small-Cell Lung Cancer: Implications for Clinical Practice

et al. 2018

View full text Add to dashboard Cite

Immune checkpoint inhibitors targeting PD-1 or PD-L1 represent a standard treatment option for patients with advanced non-small-cell lung cancer. However, a substantial proportion of patients will not benefit from these treatments, and robust biomarkers are required to help clinicians select patients who are most likely to benefit. Here, we discuss the available evidence on the utility of clinical characteristics in the selection of patients with advanced non-small-cell lung cancer as potential candidates for single-agent anti-PD-1/PD-L1 therapy, and provide practical guidance to clinicians on identifying those patients who are most likely to benefit. Recommendations on the use of immune checkpoint inhibitor in clinically challenging populations are also provided.

show abstract

mentioning

confidence: 76%

Patient Selection for Anti-PD-1/PD-L1 Therapy in Advanced Non-Small-Cell Lung Cancer: Implications for Clinical Practice

et al. 2018

View full text Add to dashboard Cite

show abstract

“…This presents a problem for a large fraction of patients with advanced‐stage NSCLC who are not surgical candidates and are frequently diagnosed via cytology materials. There are limited data available on the suitability and performance of PD‐L1 testing in cytology specimens, with very few published studies related to PD‐L1 concordance between cytology and histology specimens . These recent studies focused primarily on FFPE cytology cell blocks, and the feasibility of evaluating PD‐L1 expression and performance with cytology smears has not been investigated.…”

Section: Introductionmentioning

confidence: 99%

Programmed death ligand 1 testing in non–small cell lung carcinoma cytology cell block and aspirate smear preparations

Noll

Wang

Gong

et al. 2018

Cancer Cytopathology

101

143

View full text Add to dashboard Cite

show abstract

“…However, cytology specimens are often the only materials available, especially for patients at an advanced stage. Limited studies have compared PD‐L1 IHC on cytologic specimens and surgical specimens, and most of them had small study cohorts with PD‐L1 IHC not performed as part of routine clinical care . Our study addressed the comparability of PD‐L1 IHC on cytologic specimens and surgical specimens in a large cohort of clinical cases (265 clinical cases, including 100 cytologic specimens and 165 surgical specimens).…”

Section: Discussionmentioning

confidence: 99%

“…Most studies have evaluated PD‐L1 expression in surgical specimens, and studies of cytology specimens are limited . However, cytologic specimens are frequently the only specimens available, especially for patients at an advanced stage.…”

Section: Introductionmentioning

confidence: 99%

Programmed cell death ligand 1 expression in cytologic and surgical non–small cell lung carcinoma specimens from a single institution: Association with clinicopathologic features and molecular alterations

Mei

Shilo

Wei

et al. 2019

Cancer Cytopathology

View full text Add to dashboard Cite

Background Programmed cell death ligand 1 (PD‐L1) expression by the 22C3 pharmDx companion assay has been validated in surgical specimens to support pembrolizumab treatment decisions for patients with non–small cell lung carcinoma (NSCLC). The aims of this study were 1) to assess the adequacy of cytologic specimens for PD‐L1 evaluation and 2) to explore correlations of PD‐L1 expression with clinicopathologic and molecular features. Methods The study cohort included 100 cytology specimens (fluid [n = 28] and fine‐needle aspiration [n = 72]) and 165 surgical specimens (biopsy [n = 138] and resection [n = 27]). The PD‐L1 immunohistochemistry 22C3 assay and staining assessment were performed according to the manufacturer's instructions. PD‐L1 expression was correlated with patients' demographics, pathologic characteristics, and molecular alterations. Results One hundred forty‐two specimens (53.6%) were positive for PD‐L1 expression (≥1%). No statistically significant difference in PD‐L1 expression was identified between cytologic (56.0%) and surgical specimens (52.1%). Seventy‐four of 190 tested cases (38.9%) had genetic alterations. PD‐L1 positivity was significantly more prevalent in cases with genetic alterations than in cases without genetic alterations. Furthermore, both PD‐L1 positivity and high PD‐L1 expression (≥50%) had statistically significant associations with Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations. PD‐L1 expression had no significant association with histologic phenotypes or other clinicopathologic features. Conclusions The data indicate that cytologic specimens are comparable to surgical specimens for PD‐L1 evaluation. The association of PD‐L1 expression with KRAS mutations may have clinical relevance in selecting patients with NSCLC for immunotherapy.

show abstract

Programmed death‐ligand 1 testing of lung cancer cytology specimens obtained with bronchoscopy

Cited by 65 publications

References 15 publications

Patient Selection for Anti-PD-1/PD-L1 Therapy in Advanced Non-Small-Cell Lung Cancer: Implications for Clinical Practice

Patient Selection for Anti-PD-1/PD-L1 Therapy in Advanced Non-Small-Cell Lung Cancer: Implications for Clinical Practice

Programmed death ligand 1 testing in non–small cell lung carcinoma cytology cell block and aspirate smear preparations

Programmed cell death ligand 1 expression in cytologic and surgical non–small cell lung carcinoma specimens from a single institution: Association with clinicopathologic features and molecular alterations

Contact Info

Product

Resources

About